Literature DB >> 19299374

Stability of extemporaneously prepared moxifloxacin oral suspensions.

David J Hutchinson1, Cary E Johnson, Kristin C Klein.   

Abstract

PURPOSE: The stability of extemporaneously prepared moxifloxacin oral suspensions was studied.
METHODS: An oral suspension of moxifloxacin 20 mg/mL was prepared by thoroughly grinding three 400-mg tablets of moxifloxacin in a glass mortar. Thirty milliliters of Ora-Plus and 30 mL of either Ora-Sweet or Ora-Sweet SF were mixed and added to the powder to make a final volume of 60 mL. Three identical samples of each formulation were prepared and placed in 2-oz amber plastic bottles with child-resistant caps and were stored at room temperature (23-25 degrees C). A 1-mL sample was withdrawn from each of the six bottles with a micropipette immediately after preparation and at 7, 14, 28, 60, and 90 days. After further dilution to an expected concentration of 8 microg/ mL with sample diluent, the samples were assayed in duplicate by stability-indicating high-performance liquid chromatography. Stability was defined as the retention of at least 90% of the initial concentration.
RESULTS: At least 99% of the initial moxifloxacin remained throughout the 90-day study period in both preparations. There were no detectable changes in color, odor, taste, and pH and no visible microbial growth in any sample.
CONCLUSION: Extemporaneously compounded suspensions of moxifloxacin 20 mg/mL in a 1:1 mixture of Ora-Plus and Ora-Sweet or Ora-Sweet SF were stable for at least 90 days when stored in 2-oz amber plastic bottles at room temperature.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19299374     DOI: 10.2146/ajhp080152

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  2 in total

1.  Photodegradation of moxifloxacin in aqueous and organic solvents: a kinetic study.

Authors:  Iqbal Ahmad; Raheela Bano; Syed Ghulam Musharraf; Sofia Ahmed; Muhammad Ali Sheraz; Qamar ul Arfeen; Muhammad Salman Bhatti; Zufi Shad
Journal:  AAPS PharmSciTech       Date:  2014-08-20       Impact factor: 3.246

2.  Moxifloxacin Pharmacokinetics, Cardiac Safety, and Dosing for the Treatment of Rifampicin-Resistant Tuberculosis in Children.

Authors:  Kendra K Radtke; Anneke C Hesseling; J L Winckler; Heather R Draper; Belen P Solans; Stephanie Thee; Lubbe Wiesner; Louvina E van der Laan; Barend Fourie; James Nielsen; H Simon Schaaf; Radojka M Savic; Anthony J Garcia-Prats
Journal:  Clin Infect Dis       Date:  2022-04-28       Impact factor: 20.999

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.